Sepsis, among other pathologies, is an endotoxin tolerance (ET)-related disease. On admission, we classified 48 patients with sepsis into 3 subgroups according to the ex vivo response to lipopolysaccharide. This response correlates with the Acute Physiology and Chronic Health Evaluation (APACHE) II score and the ET degree. Moreover, the ET-related classification determines the outcome of these patients. Programmed cell death-ligand 1 (PD-L1) expression on septic monocytes is also linked with ET status. In addition to the regulation of cytokine production, one of the hallmarks of ET that significantly affects patients with sepsis is T-cell proliferation impairment or a poor switch to the adaptive response. PD-L1/programmed cell death-1 (PD-1) blocking and knockdown assays on tolerant monocytes from both patients with sepsis and the in vitro model reverted the impaired adaptive response. Mechanistically, the transcription factor hypoxia-inducible factor-1α (HIF1α) has been translocated into the nucleus and drives PD-L1 expression during ET in human monocytes. This fact, together with patient classification according to the ex vivo lipopolysaccharide response, opens an interesting field of study and potential personalized clinical applications, not only for sepsis but also for all ET-associated pathologies.
The discovery and characterization of immune checkpoints (ICs) adds a new parallel window of study in which cell-to-cell interaction could have an important role beyond cancer pathologies [1] . The surface ICs might be able to act as ligands of lymphocyte receptors, modulating the duration and range of the adaptive immune response. ICs can act as both stimulatory and adaptive response inhibitors. Within the inhibitory ICs, the B7 superfamily of molecules and the ligand of programmed cell death-ligand 1 (PD-L1) proteins emerge as promising molecules in various clinical contexts [2] [3] [4] [5] . In this regard, PD-L1 overexpression on sepsis monocytes has already been reported [6] [7] [8] , and it was associated with risk stratification and mortality in patients with sepsis [9] . One of the complications reported in these patients is a refractory state subsequent to endotoxin challenge; a phenomenon called endotoxin tolerance (ET), which also takes place in other pathologies such as cancer [10] [11] [12] . However, PD-L1 nucleoside transporter involvement in ET status development during sepsis, its control of the impaired adaptive response, and the molecular mechanism involved are open questions.
Sepsis should be defined as a life-threatening organ dysfunction caused by a deregulated host response to infection [13] ; it is currently a leading cause of death in intensive care units worldwide [14] . A number of therapeutic strategies to treat human sepsis, which are different from antimicrobial and fluid resuscitation treatments, have failed in clinical trials, and solid biomarkers for sepsis are still lacking [15] . The reason for such a scenario can be attributed to the dynamic nature of the pathology, as well as important species-specific differences in innate responses between mouse model systems and human patients [16, 17] . The latter indicates the crucial importance of studies on human samples instead of on animal models.
Two phases have been recognized in this disease: an early inflammatory phase and a late immunosuppressive stage [18] [19] [20] ; however, these 2 phases can overlap [10, 19] . In this regard, monocytes/macrophages are believed to play an important role in orchestrating the host immune response during sepsis [10, 19] . They participate in both phases of sepsis by releasing inflammatory cytokines that contribute to a "cytokine storm" and adopt an ET phenotype, whereupon they are unable to respond to secondary infections [19] . This ET status, despite the strong regulation of cytokine production to control tissue damage and the manifestation of several pathological states [10, 21] , does not constitute an immunoparalysis but rather a reprogramming that triggers other mechanisms, such as high phagocytosis activity, tissue remodeling, and antimicrobial activity [10, 21] . In accordance with our previous report, all these biological activities are controlled by hypoxia-inducible factor-1α (HIF1α) expression [21] .
As previously mentioned, however, another primary ET hallmark during sepsis is the monocyte/macrophage inability to step up the adaptive response, which is potentially responsible for a poor evolution during sepsis [10, 11, 19, 21] . Decreased human leukocyte antigen (HLA)-antigen D-related (DR) expression has been described during ET in monocytes, reducing the switch to the adaptive response [19] . In addition, polarization of the adaptive response has been reported in lipopolysaccharide (LPS)-injected healthy donors and in murine polymicrobial sepsis [22] . These observations highlight the importance of the interaction between monocytes and lymphocytes and its role in T-cell exhaustion [20] .
In the current study, we classified 48 patients with sepsis on admission according to their ET state and evaluated the influences of PD-L1/PD-1 crosstalk on immune response. We demonstrated that the induction of an adaptive response was impaired in those patients locked in a severe ET status, which was dependent on the PD-L1/PD-1 pathway. Mechanistically, HIF1α drove PD-L1 expression in human tolerant monocytes, impairing the adaptive response. Knocking down PD-L1 in tolerant monocytes using HIF1α and PD-L1 small interfering ribonucleic acids (siRNAs) increased T-cell proliferation, recovering the adaptive response. Our data shed light on the molecular and cellular basis of human sepsis progression that might inform the development of targeted therapeutic interventions.
MATERIALS AND METHODS

Study Design
The study was conducted in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Committee for Human Subjects of La Paz University Hospital. All the participants provided written consent for the study. Patients who fulfilled the diagnostic criteria for sepsis according to the Society of Critical Care Medicine and the European Society of Intensive Care Medicine international conferences [23, 24] were included in the study. Blood samples were collected at the time of admission, before any therapy, and sepsis was confirmed using clinical and analytical data. Note that the included patients were not on any type of intensive therapy, including pressors. Exclusion criteria: chronic inflammatory diseases (except asthma), presence of hematological malignancies, treatment with steroids and/or immunosuppressive drugs in the last month, previous presence of severe liver failure (serum aspartate aminotransferase and/or alanine aminotransferase >100 IU/L, prothrombin time <60% and total bilirubin <60 mmol/L), renal failure (plasma creatinine >200 μmol/L), HIV/AIDS, hepatitis B or C, and pregnancy. The clinical data of the patients included in the study are summarized in Table 1  and in Supplementary Table 1 and Table 2 .
Reagents
Roswell Park Memorial Institute (RPMI) medium (Invitrogen) was used for the cell cultures. The following antibodies were used: anti-CD14, antihuman leukocyte antigen-antigen D-related (anti-HLA-DR), anti-CD3 (Immunostep), and anti-PD-L1 (Miltenyi Biotec). The LPS from Salmonella abortus was a kind gift from Dr Galanos (Max Planck Institute of Immunobiology and Epigenetics). For the phagocytosis assays, an Escherichia coli K12 lineage was transformed with a plasmid containing green fluorescence protein (GFP). Carboxyfluorescein succinimidyl ester (CFSE) for the proliferation assays was purchased from Thermo Fisher Scientific. The lymphocyte stimulus pokeweed (PWD) was purchased from Sigma-Aldrich. To inhibit PD-1/ PD-L1 interaction, a fully human immunoglobulin G4 (IgG4; S228P) anti-PD-1 receptor-blocking monoclonal antibody was used (Bristol-Myers Squibb). The human HIF1α plasmid was a kind gift from Dr del Peso (Institute for Biomedical Research Alberto Sols). The PD-L1 (s26549) and HIF1α (s6539) siRNAs were purchased from Thermo Fisher Scientific. All the reagents used for the cell cultures were endotoxin-free, as assayed with the Limulus amebocyte lysate test (Cambrex).
Monocyte and Lymphocyte Isolation From Peripheral Blood
The peripheral blood mononuclear cells were isolated using Ficoll-Plus gradient (GE Healthcare Bio-Sciences) [19] . The monocytes and lymphocytes were separated by adherence, comprising monocytes as adherent cells and lymphocytes as nonadherent cells [19] . For mechanistic and messenger RNA (mRNA) expression studies involving monocytes, a specific isolation kit from Miltenyi Biotec was used. Cell purity was checked by flow cytometry (>95% positive cells).
Cytometric Bead Array
Tumor necrosis factor-α (TNFα), interleukin (IL)-1β, IL-6, and IL-10 protein levels in the culture supernatants were determined using the Human Inflammatory cytometric bead array (CBA) kit (BD Biosciences), following the manufacturer's protocol. The samples were collected by flow cytometry using a BD FACSCalibur flow cytometer (BD Biosciences).
Flow Cytometry Analysis
For marker staining, the cells were labeled with: allophycocyanin (APC)-conjugated antihuman CD14, fluorescein isothiocyanate-conjugated antihuman HLA-DR, APC-conjugated anti-human CD3 (all from Immunostep, Spain), and phycoerythrin-conjugated antihuman PD-L1 (Miltenyi Biotec). Matched isotype antibodies were used as negative controls. The cells were incubated for 30 minutes at 4ºC in the dark. The data were acquired by flow cytometry using a BD FACSCalibur flow cytometer (BD Biosciences) and analyzed with FlowJo vX.0.7 software (FlowJo, LLC).
Proliferation Assays
In a 96-well plate, 10 4 monocytes per well were cultured. The monocytes were stimulated or not with LPS (5 ng/mL) for 1 hour. The monocytes were then washed and the medium replaced with fresh RPMI medium. Thereafter, autologous CFSE-labeled lymphocytes were added corresponding to a 1:5 monocyte:lymphocyte ratio per well. The cells were then stimulated or not with PWD (2.5 µg/mL) and treated with 5 µg/mL of a fully human IgG4 (S228P) anti-PD-1 receptor-blocking monoclonal antibody (Bristol-Myers Squibb).
Monocyte Nucleofection
For knockdown (PD-L1 and HIF1α siRNAs) and HIF1α overexpression assays, human monocytes were nucleofected as we previously described [25] , using an Amaxa Nucleofector (Lonza Group).
Phagocytosis
The monocytes were exposed to bacteria (GFP-E. coli K12) for 2 hours. The cells were washed and kept in 300 mg/mL gentamicin (Laboratorios Normon) for 30 minutes. Phagocytosis was analyzed by flow cytometry of GFP + cells, as reported previously [12] .
HIF1α Pathway Assays
Nuclear and cytoplasmic cell extracts were isolated from isolated human monocytes after an ET model using the Nuclear Extract Kit (Active Motif). HIF1α enzyme-linked immunosorbent assay (ELISA; Abcam) was performed according to the manufacturer's instructions. Chromatin immunoprecipitation (ChIP) was performed with lysates prepared from isolated human monocytes using the Human/Mouse HIF1α ExactaChIP Chromatin IP Kit (R&D Systems). Finally, DNA were isolated and used in polymerase chain reactions (PCRs). The products (hypoxia response element [HRE] sites) were amplified using primers for interleukin-1 receptor-associated
5'TCCCTCTTAGTGCCTCTCCAA-3' (reverse); PD-L1 (7), 5'TGCATACAGTGGTTTTGGGA-3' (forward), 5'AGGAGTTCTACTTCCCTGAGT3' (reverse). All the primers were synthesized by Bonsai Biotech.
RNA Isolation and Quantification
The cells were washed once with phosphate-buffered saline and the RNA was isolated using the High Pure RNA Isolation Kit (Roche Diagnostics). The complementary DNA (cDNA) was obtained by reverse transcription of 1 mg RNA using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). The gene expression levels from cDNA were analyzed by real-time quantitative PCR using the Light Cycler system (Roche Diagnostics). The real-time quantitative PCRs were performed using the QuantiMix Easy SYG kit from Biotools and specific primers. The results were normalized to the expression of β-actin, and the cDNA copy number of each gene of interest was determined using a 7-point standard curve. The products were amplified using specific primers as described previously [19, 21, [25] [26] [27] [28] .
Statistical Analyses
The number of experiments analyzed is indicated in each figure. The statistical significance was calculated using a MannWhitney, paired t test, or 1-way analysis of variance, depending on the specific assay. The correlations were assessed using Spearman's rank-order correlation for non-normally distributed data. The statistical significance was set at P < .05, and the statistical analyses were conducted using Prism 5.0 software (GraphPad).
RESULTS
PD-L1 Expression in Patients With Sepsis Correlates With Their ET Status
Blood samples from 48 patients with sepsis were stimulated with LPS for 3 hours, and then TNFα levels were analyzed. An inverse correlation between the Acute Physiology and Chronic Health Evaluation (APACHE) II score and TNFα production was found ( Figure 1A ). This analysis allowed us to classify patients with sepsis into 3 subgroups with the same number of components, taking into account the production of TNFα (I, II, and III; see Figure 1A and Table 1 ). The analysis of PD-L1 expression on monocytes from these patients indicated a dependency on this classification. Those patients classified as subgroup I expressed higher levels of PD-L1 than those belonging to subgroups II and III ( Figure 1B) , with statistical significance in the case of subgroup III. In addition, T-cell proliferation after coculture with the patients' monocytes in the presence of the classical mitogen lectin PWD was not impaired in subgroups II and III, but was in subgroup I. In the last case, incubation with an anti-PD-1 antibody restored the process, indicating the role of PD-L1/PD-1 crosstalk in this context ( Figure 1C) . Curiously, an analysis of cytokine generation after LPS challenge in whole blood, as well as HLA-DR, IRAK-M, and HIF1α expression in monocytes, linked subgroup I with a patent refractory state or ET [11, 21] , whereas subgroup III did not exhibit the hallmarks of ET (Figure 2 ). Note that subgroup II represented an intermediate status. Finally, an analysis of absolute lymphocyte counts indicated a significant reduction in subgroup I compared with subgroup III (Supplementary Figure 1A) . Apoptosis is also higher in T cells from subgroup I than from subgroup III; this significant difference was negated in the presence of a blocking anti-PD-1 antibody (Supplementary Figure 1B) . Table 1 and  Supplementary Table 1 summarize the patient's clinical parameters according to classification. Note that the APACHE II, quick Sequential Organ Failure Assessment (qSOFA) scale, Glasgow coma scale, heart rate, oxygen saturation, lactate, and outcome showed significant differences between subgroups, and subsequently, a link with ET status.
PD-L1/PD-1 Crosstalk Controls the Impairment of T-Lymphocyte Proliferation During ET
To study the PD-L1/PD-1 crosstalk implication in ET in depth, a well-established model of ET was used (Supplementary Figure  2A) [19, 21, 25, 28] . A significant reduction in TNFα, together with an increment in IL-10 (Supplementary Figure 2B) , a decreased expression of HLA-DR (Supplementary Figure 2C) , impaired T-cell proliferation (Supplementary Figure 2D) , patent high phagocytosis, and upregulation of HIF1α (Supplementary Figure 2E and 2F ) indicated that the model showed the previous established ET hallmarks [11, 21] . The tolerant monocytes generated exhibited higher PD-L1 levels than in the controls ( Figure 3A and 3B) , and the previously reported T lymphocyte proliferation impairment after coculture with tolerant monocytes [19, 21] was negated in the presence of anti-PD-1 ( Figure  3C ). Knockdown assays in monocytes also demonstrated the crucial role of PD-L1/PD-1 crosstalk in the control of T-cell proliferation impairment during ET ( Figure 3D and 3E) . However, a lack of PD-L1 did not restore the profile of cytokine production after endotoxin challenge, which was affected during ET ( Figure 3F ).
HIF1α Drives PD-L1 Expression on ET Monocytes
We have previously reported the crucial role of HIF1α in the overexpression of the negative regulator of inflammation, IRAK-M, during ET in monocytes isolated from patients with sepsis [21] . In fact, during ET, we detected both an upregulation of HIF1α mRNA ( Figure 4A ) and an increase in HIF1α translocation into the nucleus ( Figure 4B and 4C) . Overexpression of HIF1α in human monocytes resulted in a patent PD-L1 upregulation ( Figure 5A ). To investigate whether PD-L1 was a direct HIF1α target gene in humans, we searched for potential HIF1α binding sites in the proximal promoter of the human PD-L1 gene, using bioinformatics approaches (www.ensembl.org). As shown in Figure 5B , we found 7 putative HRE sites containing the consensus sequence (A/G)CGTG within the human PD-L1 gene. Using a ChIP assay, we demonstrated HIF1α binds chromatin sites related to the PD-L1 promoter (HRE4 and 5, HRE6, and HRE7) in tolerant human monocytes ( Figure 5C and 5D ). Human HIF1α-transfected monocytes were used as a positive control. Moreover, the well-known negative regulator of inflammation, IRAK-M, which is controlled by HIF1α [21] , was included as an additional positive control in the assay ( Figure  5C and 5D). Eventually, PD-L1 expression was significantly reduced in siRNA-HIF1α-tolerant monocytes ( Figure 5E ), restoring T-cell proliferation when lymphocytes were cocultured with these cells ( Figure 5F ).
HIF1α Modulates T-Cell Response Through PD-L1 Overexpression in ET Patients With Sepsis
To corroborate the data obtained in the ET model, we attempted to investigate the role of HIF1α on PD-L1 overexpression in a new small cohort of patients with sepsis. These patients were classified into 3 subgroups (I, II, and III) according to their ET status, following the same criteria shown in Figure 1 (details in Supplementary Table 2 ). Both HIF1α and PD-L1 knockdown significantly reduced PD-L1 expression in the tolerant patients in subgroup I when compared with the appropriate controls ( Figure 6A ). Based on this finding, we tested whether the HIF1α knockdown in subgroup I also coordinated the T-lymphocyte response. Monocytes, transfected with HIF1α or PD-L1 siRNAs, were cocultured with CFSE-labeled autologous lymphocytes and stimulated with PWD. HIF1α, as well as PD-L1 knockdown, resulted in a significant increment of T-cell proliferation ( Figure 6B ). Note that levels of PD-L1 and HIF1α mRNA were assessed to validate the knockdown assays (data not shown).
DISCUSSION
Some studies of patients with sepsis have reported the upregulation of both PD-L1 and PD-1 on monocytes and T cells, respectively [6, 8, 9] . At least 2 observational studies have been developed to identify potential changes in the PD-L1/PD-1 crosstalk during sepsis, still awaiting results (NCT01161745 and NCT01976884). In the current study, we implemented an approach to show that blood monocytes can reveal the status of the innate immune response in patients with sepsis, as well as a potential therapeutic strategy to rescue them from an immunosuppressive phase. The detrimental features of sepsis have been explained due to the damaging effects caused by overinflammation and systemic inflammatory response syndrome [23, 29] . Several anti-inflammatory therapies have been developed against the proinflammatory phase of sepsis. However, all the therapies, including antiendotoxin [30] , anti-TNFα [31, 32] , anti-IL-1 [33] and Toll-like receptor inhibitors [34, 35] , have failed in some clinical trial phase. There is increasing evidence highlighting the relevance of immunosuppression [20, 36, 37] and the alternative noninflammatory activation [21, 25] of the innate immune system in sepsis evolution. Death from sepsis, in most cases, is not due to overinflammation, which can be controlled with antibiotics and steroids, but instead reflects host immunosuppression that confers a high risk of nosocomial infection [20, 38] . A potential mechanism of immunosuppression in patients with sepsis is the induction of ET, a process by which host immune cells become refractory to further endotoxin challenge [10, 11] . Our previous studies indicated that through the control of the transcription of a set of genes, such as IRAKM, VEGFA, and MMP, HIF1α governs most of the monocyte reprogramming that takes place during an ET state, including the downregulation of inflammation and a considerable increase in phagocytosis, antimicrobial activity, remodeling, and tissue repair [21] . The present data extend the HIF1α control to one of the most important ET hallmarks: the impaired adaptive response; and it involved the immune checkpoint PD-L1/PD-1 in this context (see resume in Figure 7) . Although the implication of nuclear factor-κB in the control of PD-L1 expression on human monocytes has been proposed [39] , it is also largely known that nuclear factor-κB is mainly inactive in ET monocytes [11, 19, 21, 25, 26, 28] . Thus, translocation of HIF1α is the most convincing explanation for elevated PD-L1 expression on tolerant human monocytes. Previously, Zaeem Noman and colleagues [40] have demonstrated that HIF1α controls PD-L1 expression in mouse myeloid-derived suppressor cells, altering cytokine production. Note that our findings have indicated that the knockdown of PD-L1 did not modify the cytokine expression profile after LPS challenge in human monocytes. However, other authors have reported a reversion of the inflammatory response after an ex vivo anti-PD-L1 antibody treatment [8] . This apparent contradiction could be explained by the potential effect of the and tolerant monocytes stimulated with LPS (gray). C, Control (black bars) and tolerant (gray bars) human monocytes were challenged with 5 ng/mL LPS for 1 hour and cocultivated with CFSE-labeled autologous lymphocytes (ratio 1:5); as a negative control, nonstimulated monocytes were used (empty bars). Next, cultures were stimulated with both PWD (2.5 µg/mL) and/or an anti-PD-1 monoclonal antibody (5 µg/mL) for 5 days. Percentages of proliferative CD3 + population measured by FACS (n = 6) are shown. D, Control (black bars) and tolerant (gray bars) human monocytes were transfected with control siRNA or PD-L1 siRNA (30 nM) and challenged with 5 ng/mL LPS for 1 hour, as negative nonstimulated control monocytes were used (empty bars). Percentages of PD-L1 + cells gated on the CD14 + population are shown (n = 6). Next, the same cells were cocultured with CFSE-labeled autologous lymphocytes (ratio 1:5). Then the cultures were stimulated or not with PWD (2.5 µg/mL) for 5 days. E, Percentages of proliferation on the CD3 + population measured by FACS (n = 6) are shown. F, Control (Mφ) and tolerant (tol-Mφ) human monocytes were transfected with control siRNA (white bars) or PD-L1 siRNA (30 nM, gray bars) and challenged with 5 ng/mL LPS for 6 hours. Then TNFα and IL-10 production (pg/mL) quantified by CBA are shown (n = 6). *P < .05; **P < .01; ***P < .001 using a paired t test. Abbreviations: CBA, cytometric bead array; CFSE, carboxyfluorescein succinimidyl ester; FACS, fluorescent-activated cell sorter; IL, interleukin; LPS, lipopolysaccharide; PD-1, programmed cell death-1; PD-L1, programmed cell death-ligand 1; PWD, pokeweed; siRNA, small interfering ribonucleic acid; TNFα, tumor necrosis factor-α.
anti-PD-L1 antibody on monocytes [41] . Mechanistically, our present findings and previously reported data have indicated that HIF1α, but not PD-L1, inhibits the inflammatory response via IRAK-M upregulation [21] . PD-L1 regulation by HIF1α has been previously described in renal carcinoma tumor cells [42, 43] and mouse myeloid-derived suppressor cells [40] . However, our findings added a solid demonstration of active HREs in the human PD-L1 transcript by ChIP assay in a new type of cell, human blood monocytes, and a different clinical context, infectious disease, in which this phenomenon takes place.
Blockage of PD-L1/PD-1 crosstalk using an anti-PD-1 antibody has meant a revolutionary treatment for many types of cancers, such as melanoma, lung, and renal cancers [1, 44, 45] . In mice with sepsis, the administration of anti-PD-L1/PD-1 antibodies prevents lymphocyte depletion [46] and improves survival in a model of Candida albicans sepsis [47] , suggesting the necessity of translational implementation in human patients. Also, the reported low absolute lymphocyte count during sepsis [48] could be explained by a potential PD-L1-induced apoptosis (Supplementary Figure 1) .
In terms of a clinical application for our sepsis results, one of the first questions to emerge would be for which septic patients to apply a PD-L1/PD-1 blocking strategy and at what moment in time. Our results indicate that those patients who exhibited an ET status on admission also generated high severity scores (APACHE II and qSOFA) and expressed high levels of PD-L1 in their circulating monocytes. These patients (subgroup I; see Figure 1 and Table 1 ) exhibited the lowest rate of T-cell proliferation, which is corrected by blocking both PD-L1/PD-1 crosstalk and knockdown assays. The patients in subgroup II have an intermediate state and, despite having higher levels of PD-L1 than subgroup III, do not present a manifest affectation of the induction of the adaptive response. Shao et al's study indicated that PD-L1 expression after 3-4 days of sepsis was associated with risk stratification and mortality [9] . In our cohort, however, a classification of patients with sepsis on admission and before any treatment, according to their ET degree and PD-L1 expression on circulating monocytes, would be advisable to identify those patients susceptible to treatment with anti-PD-1. The ET-related classification is more accurate in stratifying the severity of patients at admission than classical scores, probably due to those scores being based on severity surrogate markers; in contrast, ET is a direct measure of the inflammatory/immunosuppressive process that is implicated in the final outcome. This ET-related classification is able to determine the outcome of these patients (Table 1) . APACHE II was a better severity predictor of ET status than q-SOFA (P = .009 vs P = .033; see Table 1 ). Unlike APACHE II, SOFA and qSOFA have recently been recommended as a standard severity classification score for sepsis based on retrospective studies [13] ; some reports that attempt to validate the qSOFA score obtained different results [49, 50] .
In conclusion, the present study has demonstrated that human blood sepsis monocytes under ET expressed high levels of PD-L1 on their cell surface via the induction of HIF1α, and governed the impaired induction of T-cell proliferation during ET. The mechanism described completes the picture of the ET hallmarks and the factors involved. In addition, our findings open a potential clinical application, not only for patients with sepsis but also for those ET-related pathologies. and nuclear (C) fractions are shown (n = 5). *P < .05; **P < .01; ***P < .001 using a paired t test. Abbreviations: ELISA, enzyme-linked immunosorbent assay; HIF1α, hypoxia-inducible factor-1α ; LPS, lipopolysaccharide; mRNA, messenger ribonucleic acid; qPCR, quantitative polymerase chain reaction. Mφ / anti-HIF1α ( 
HIF1α transfected monocytes with anti-HIF1α for precipitation; and (4) HIF1α transfected monocytes with control IgG1 for precipitation. E, Control (black bars) and tolerant (gray bars) human monocytes were transfected with control siRNA or HIF1α siRNA (30 nM) and challenged with 5 ng/mL LPS for 1 hour, as negative nonstimulated control monocytes were used (empty bars). The percentages of PD-L1 + cells on the gated CD14 + population are shown. F, The same cells were cocultured with CFSE-labeled autologous lymphocytes (ratio 1:5). Next, they were stimulated or not with PWD (2.5 µg/mL) for 5 days. The percentages of proliferative CD3 + population are shown (n = 5). *P < .05; **P < .01; using a paired t test. Abbreviations: CFSE, carboxyfluorescein succinimidyl ester; ChIP, chromatin immunoprecipitation; HIF1α, hypoxia-inducible factor-1α; HRE, hypoxia-response element; IgG1, immunoglobulin G1; IRAK-M, interleukin-1 receptor-associated kinase-M; LPS, lipopolysaccharide; PD-L1, programmed cell death-ligand 1; pHIF1α, HIF1α protein; PWD, pokeweed; siRNA, small interfering ribonucleic acid. shown. B, Nucleofected sepsis monocytes from patients belonging to subgroup I (n = 3) were cocultivated with CFSE-labeled autologous lymphocytes (ratio 1:5), 2 replicates for each patient. Next, cultures were stimulated with PWD (2.5 µg/ml) for 5 days. Percentages of proliferative CD3 + population measured by FACS are shown. *P < .05; **P < .01; using a Mann-Whitney test. Abbreviations: CFSE, carboxyfluorescein succinimidyl ester; ET, endotoxin tolerance; FACS, fluorescent-activated cell sorter; HIF1α, hypoxia-inducible factor-1α; PD-L1, programmed cell death-ligand 1; PWD, pokeweed; siRNA, small interfering ribonucleic acid.
